Although TNF-α inhibitors have been considered as potential therapeutic agents, evidence suggests that their use may raise the risk of co-infections (such as bacterial and mycobacterial) in COVID-19 patients, potentially worsening the disease (Guo et al., 2022). This evidence concerns the gene TNF and COVID-19.